D Dingli

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Mathematical modeling of cancer radiovirotherapy
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Math Biosci 199:55-78. 2006
  2. pmc Dynamics of haemopoiesis across mammals
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Proc Biol Sci 275:2389-92. 2008
  3. pmc Angiomatoid fibrous histiocytoma in a 25-year-old male
    Aaron Mansfield
    Division of Hematology, Mayo Clinic, Rochester, MN
    Rare Tumors 2:e20. 2010
  4. pmc Schnitzler syndrome: an under-diagnosed clinical entity
    Tania Jain
    Haematologica 98:1581-5. 2013
  5. ncbi request reprint Interaction of measles virus vectors with Auger electron emitting radioisotopes
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 337:22-9. 2005
  6. pmc Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
    D Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Cancer 101:1130-6. 2009
  7. pmc How best to use new therapies in multiple myeloma
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States
    Blood Rev 24:91-100. 2010
  8. doi request reprint Some dynamic aspects of hematopoietic stem cells
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
    Stem Cell Rev 4:57-64. 2008
  9. pmc Stochastic dynamics and the evolution of mutations in stem cells
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    BMC Biol 9:41. 2011
  10. pmc Compartmental architecture and dynamics of hematopoiesis
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 2:e345. 2007

Detail Information

Publications100

  1. ncbi request reprint Mathematical modeling of cancer radiovirotherapy
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Math Biosci 199:55-78. 2006
    ..Furthermore, we evaluated relevant therapeutic scenarios for radiovirotherapy, and offered elements for optimization...
  2. pmc Dynamics of haemopoiesis across mammals
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Proc Biol Sci 275:2389-92. 2008
    ..This unified view, which is compatible with the existing data, suggests that there was no need for major adaptations in the architecture of haemopoiesis across mammals...
  3. pmc Angiomatoid fibrous histiocytoma in a 25-year-old male
    Aaron Mansfield
    Division of Hematology, Mayo Clinic, Rochester, MN
    Rare Tumors 2:e20. 2010
    ..Herein we describe a case report of a 25-year-old gentleman whose presentation was concerning for lymphoma. Subsequently we review of the relevant literature...
  4. pmc Schnitzler syndrome: an under-diagnosed clinical entity
    Tania Jain
    Haematologica 98:1581-5. 2013
    ..Schnitzler syndrome may be present in up to 1.5% of patients with a monoclonal IgM in their serum and likely under-recognized as a clinical syndrome. ..
  5. ncbi request reprint Interaction of measles virus vectors with Auger electron emitting radioisotopes
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 337:22-9. 2005
    ..MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo...
  6. pmc Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
    D Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Cancer 101:1130-6. 2009
    ..Until now, phenotypic variability has precluded a clear-cut identification of the fundamental characteristics of a given tumour type...
  7. pmc How best to use new therapies in multiple myeloma
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States
    Blood Rev 24:91-100. 2010
    ..We also discuss our approach to the use of these agents in specific myeloma settings...
  8. doi request reprint Some dynamic aspects of hematopoietic stem cells
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
    Stem Cell Rev 4:57-64. 2008
    ....
  9. pmc Stochastic dynamics and the evolution of mutations in stem cells
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    BMC Biol 9:41. 2011
    ..We show how stochastic effects can explain clinical observations, including extinction of acquired clonal stem cell disorders...
  10. pmc Compartmental architecture and dynamics of hematopoiesis
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 2:e345. 2007
    ..Whereas HSC replicate slowly, committed cells replicate faster as they become more differentiated...
  11. pmc Evolutionary dynamics of two related malignant plasma cell lines
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Cell Cycle 9:3792-7. 2010
    ..The evolutionary dynamics relating the two cell lines are discussed and a hypothesis is generated in regard to the mechanism of one of the phenotypic characteristics that is shared by these two cell lines...
  12. ncbi request reprint Plasma membrane phospholipid labeling to estimate tumor burden and kinetics
    David Dingli
    Division of Hematology and Department of Molecular Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Biol Ther 7:748-9. 2008
  13. ncbi request reprint Successful therapy must eradicate cancer stem cells
    David Dingli
    Program for Evolutionary Dynamics, Harvard University, One Brattle Square, Suite 6, Cambridge, Massachusetts 02138, USA
    Stem Cells 24:2603-10. 2006
    ..We explored different therapeutic scenarios to illustrate the properties required from novel therapeutic agents for successful tumor treatment. We show that successful therapy must eradicate tumor stem cells...
  14. pmc Progenitor cell self-renewal and cyclic neutropenia
    D Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cell Prolif 42:330-8. 2009
    ..Mutations in neutrophil elastase gene (ELA2) have been found in more than half of patients with CN. However, neither connection between phenotypic expression of ELA2 and CN nor the mechanism of cycling is known...
  15. doi request reprint Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
    D Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 74:913-8. 2010
    ..Amyloidosis may present with autonomic neuropathy (AN) that renders peritransplant care problematic. The purpose of this study was to determine the outcome of patients with AN during and after ASCT...
  16. pmc Dynamics of multiple myeloma tumor therapy with a recombinant measles virus
    D Dingli
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Cancer Gene Ther 16:873-82. 2009
    ..Such realistic models can be used to understand experimental observations, explore alternative therapeutic scenarios and develop techniques to optimize therapy...
  17. pmc Neutral evolution in paroxysmal nocturnal hemoglobinuria
    David Dingli
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 105:18496-500. 2008
    ..The model also accounts for the occurrence of spontaneous cure in PNH, consequent on clonal extinction. Thus, a clonal advantage may not be always necessary to explain clonal expansion in PNH...
  18. ncbi request reprint Anagrelide: an update on its mechanisms of action and therapeutic potential
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 4:533-41. 2004
    ..The main side effects of the medication are discussed, as well as the potential future developments in the field...
  19. pmc Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
    M Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1934-9. 2010
    ..The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma...
  20. doi request reprint Impact of early relapse after auto-SCT for multiple myeloma
    S Kumar
    Divisions of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:413-20. 2008
    ..Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches...
  21. pmc Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 28:1122-8. 2014
    ..Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably. ..
  22. ncbi request reprint Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center
    A Dispenzieri
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 48:1302-7. 2013
    ..This difference in survival is most notable among those patients who achieve CR, suggesting very different plasma cell biology between the two diseases. ..
  23. doi request reprint SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization
    M A Gertz
    Division of Hematology, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:956-61. 2011
    ..The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors...
  24. ncbi request reprint High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
    A Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Heart 100:383-8. 2014
    ..To define whether the high sensitivity cardiac troponin T (hs-cTnT) assay in patients with immunoglobulin light chain amyloidosis (AL) improves risk prediction...
  25. doi request reprint Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 48:557-61. 2013
    ..Patients with serum troponin T >0.06 ng/mL or NT-proBNP >5000 pg/mL (not on dialysis) should not be considered candidates for SCT because of early mortality...
  26. doi request reprint Second auto-SCT for treatment of relapsed multiple myeloma
    W I Gonsalves
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55906, USA
    Bone Marrow Transplant 48:568-73. 2013
    ..Hence, auto-SCT2 is an effective and feasible therapeutic option for MM patients relapsing after other treatments, especially in patients who had a TTP of at least 12 months after their auto-SCT1...
  27. doi request reprint Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
    S K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 41:1013-9. 2008
    ..6 months for Dex and were not reached for Thal-Dex and Len-Dex groups, P=0.2. For patients undergoing early ASCT for myeloma, the nature of initial treatment utilized has no long-term impact on the outcome of ASCT...
  28. pmc Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 43:619-25. 2009
    ..Our data suggested that CY damaged the microenvironment and slowed engraftment. By lengthening the period between the completion of apheresis and stem cell reinfusion, the microenvironment may recover and result in faster engraftment...
  29. ncbi request reprint Focal and segmental glomerulosclerosis and plasma cell proliferative disorders
    David Dingli
    Division of Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:278-82. 2005
    ..FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder...
  30. pmc Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    G Srivastava
    Division of Hematology and Blood and Marrow Transplant, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:2062-6. 2013
    ..There were 21 new second malignancies after MM diagnosis (6.6%). The median survival exceeding 7 years reflects the efficacy of novel agents. The risk of second malignancies doesn't appear to be excessive in this population...
  31. doi request reprint Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:689-96. 2011
    ....
  32. pmc Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
    H Li
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Gene Ther 17:550-8. 2010
    ..The results suggest that oncolytic MVs that code for IFNbeta and NIS will be potent and versatile agents for the treatment of human mesothelioma...
  33. doi request reprint Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
    M A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 46:970-5. 2011
    ..Improved supportive care and refined patient selection have improved the safety margin of patients undergoing auto-SCT; short-term mortality showed a more than 40% decrease after 2005...
  34. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  35. ncbi request reprint Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mol Imaging Biol 8:16-23. 2006
    ..We evaluated the potential of I-124 positron emission tomography (PET)/computed tomography (CT) imaging in gene therapy animal models utilizing the sodium iodide symporter (NIS) and compared the findings to I-123 gamma camera imaging...
  36. pmc Impact of additional cytoreduction following autologous SCT in multiple myeloma
    Sk Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 42:259-64. 2008
    ....
  37. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  38. ncbi request reprint Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
    David Dingli
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 6:384-8. 2006
    ..The impact of cyclophosphamide on CR rates and TTP was evaluated...
  39. pmc Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer
    Alan R Penheiter
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    AJR Am J Roentgenol 195:341-9. 2010
    ..The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated (131)I radiotherapy in this tumor model...
  40. pmc Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
    R M Myers
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 82:700-10. 2007
    ..On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 x 10(4) TCID50/kg (10(6) TCID50 per patient)...
  41. ncbi request reprint A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    A K Stewart
    Department of Medicine, Division of Hematology Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Leukemia 21:529-34. 2007
    ..Conversely, the 75% of patients remaining have more favorable outcomes using existing - albeit non-curative - therapeutic options...
  42. ncbi request reprint Genetically targeted radiotherapy for multiple myeloma
    David Dingli
    Mayo Clinic and Foundation, Rochester, MN, USA
    Blood 102:489-96. 2003
    ..We conclude that lentivectors can be transcriptionally targeted for myeloma cells and the use of hNIS as a therapeutic gene for myeloma in combination with 131I needs further exploration...
  43. ncbi request reprint In vivo and in silico studies on single versus multiple transplants for multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:734-9. 2007
    ..TTP after tandem transplants (with its higher associated mortality) cannot be superior to TTP achieved with optimally timed serial transplants. Individualized HDT-ASCT for patients with MM is possible and may optimize results...
  44. ncbi request reprint Stochastic dynamics of hematopoietic tumor stem cells
    David Dingli
    Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts 02138, USA
    Cell Cycle 6:461-6. 2007
    ..For input parameters compatible with both the natural history of human cancer and mouse models, our results show how stochastic dynamics alone may lead to both remission in some cases and rapid expansion in others...
  45. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  46. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  47. pmc Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors
    A R Penheiter
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Gene Ther 19:279-87. 2012
    ....
  48. doi request reprint Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization
    H V Naina
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55906, USA
    Bone Marrow Transplant 46:291-3. 2011
    ..Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization...
  49. ncbi request reprint Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Intern Med 43:540-7. 2004
    ..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
  50. ncbi request reprint On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria
    Arne Traulsen
    Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, USA
    Stem Cells 25:3081-4. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  51. pmc Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
    S Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 46:943-9. 2011
    ..This study suggests that PB-CD34 thresholds should be based on collection target to allow for early intervention and to prevent collection failures...
  52. pmc Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy
    S K Kumar
    Division of Hematology, Blood and Marrow Transplantation, Mayo Clinic, Rochester, MN, USA
    Bone Marrow Transplant 49:201-5. 2014
    ..IV plerixafor is an effective strategy for mobilization with low failure rate and is well tolerated. It offers flexibility with a schedule of early-morning infusion followed by apheresis later in the day. ..
  53. ncbi request reprint Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies
    T D Shanafelt
    Mayo Clinic College of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:707-12. 2006
    ..An NCI sponsored phase I/II trial of de-caffeinated green tea extracts for patients with asymptomatic, early stage CLL opened at Mayo Clinic in August 2005...
  54. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  55. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  56. pmc Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:799-802. 2009
    ..This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma...
  57. doi request reprint Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 115:2348-53; quiz 2560. 2010
    ..5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy...
  58. doi request reprint Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 51:2181-7. 2010
    ..001). The only predictor of survival was cardiac stage (p  < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival...
  59. pmc A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 85:409-13. 2010
    ..Addition of high-dose (153)Sm-EDTMP to melphalan conditioning appears to be safe, well tolerated, and worthy of further study in the context of novel agents and in the Phase III setting...
  60. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  61. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  62. ncbi request reprint Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:1656-60. 2005
    ..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
  63. pmc A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites
    Monica M Reinholz
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55906, USA
    Bone 47:12-22. 2010
    ..53). These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for TIBD...
  64. ncbi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  65. pmc Allometric scaling of the active hematopoietic stem cell pool across mammals
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America
    PLoS ONE 1:e2. 2006
    ..However, demands for blood cell formation vary across mammals and thus the size of the active stem cell compartment could vary across species...
  66. ncbi request reprint Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates
    Ayalew Tefferi
    Division of Hematology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 30:677-80. 2006
    ..In the current study, we show that microcytosis is a frequent laboratory feature in agnogenic myeloid metaplasia and investigate its clinical relevance in the particular setting...
  67. ncbi request reprint Serum M-spike and transplant outcome in patients with multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Sci 98:1035-40. 2007
    ..The significant expansion of myeloma cells after HDT-ASCT is clearly evident. Clinical trials must be designed that take into account these kinetic aspects of the disease...
  68. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  69. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  70. doi request reprint Modeling of cancer virotherapy with recombinant measles viruses
    Zeljko Bajzer
    Biomathematics Resource and Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Guggenheim 1611b, Rochester, MN 55905, USA
    J Theor Biol 252:109-22. 2008
    ..The model exhibits damped, as well as stable oscillations in a range of parameter values. These oscillatory states are organized by a Hopf bifurcation...
  71. doi request reprint Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 141:205-11. 2008
    ..Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma...
  72. ncbi request reprint Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
    ..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
  73. doi request reprint Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
    Shaji K Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:614-7. 2008
    ..The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age...
  74. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  75. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  76. ncbi request reprint In vivo imaging and tumor therapy with the sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 90:1079-86. 2003
    ..In this review, we discuss the role of the sodium iodide symporter (NIS) as a reporter and therapeutic gene for cancer gene therapy when combined with various radioactive isotopes...
  77. ncbi request reprint Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 325:157-66. 2004
    ..Iodide organification was insignificant. In vivo studies in tumors composed of mixed cell populations confirmed these observations...
  78. pmc Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene
    Stephanie K Carlson
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    AJR Am J Roentgenol 192:279-87. 2009
    ..t.) therapy of pancreatic cancer and, second, evaluate NIS as a reporter gene for in vivo monitoring and quantitation of MV-NIS delivery, viral spread, and gene expression in this tumor model...
  79. doi request reprint Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1131-8. 2008
    ..The overall 100-day survival rate was 98.9%. Our experience shows that outpatient transplant is feasible for all patients with multiple myeloma and results in shorter hospital stays and low treatment-related mortality rates...
  80. ncbi request reprint Unexplained pulmonary hypertension in chronic myeloproliferative disorders
    D Dingli
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Chest 120:801-8. 2001
    ..Prognosis in such a setting is poor and may not be influenced by aggressive treatment of the underlying hematologic disorder...
  81. ncbi request reprint Relationship between depth of response and outcome in multiple myeloma
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 25:4933-7. 2007
    ..We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS...
  82. ncbi request reprint Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:3948-54. 2002
    ..There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma...
  83. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  84. pmc Ontogenic growth of the haemopoietic stem cell pool in humans
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Proc Biol Sci 274:2497-2501. 2007
    ..It is possible that such common principles remain valid for haemopoiesis in other mammalian species...
  85. pmc Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling
    D M Rommelfanger
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Gene Ther 19:543-9. 2012
    ..Strategies that reduce tumor burden without suppressing the immune response and methods that maximize the amount of virus delivered to the tumor should optimize tumor control in this model system...
  86. ncbi request reprint Pulmonary hypertension in patients with amyloidosis
    D Dingli
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Chest 120:1735-8. 2001
    ..PH is an unusual complication of amyloidosis. Patients develop PH late in the disease process and do not have a worse prognosis compared to other patients with cardiac amyloidosis. PH is a marker of advanced amyloidosis...
  87. ncbi request reprint Emerging therapies for multiple myeloma
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 23:407-15. 2009
    ..The use of these agents in specific settings is also discussed...
  88. ncbi request reprint Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:1985-9. 2006
    ..Such information is particularly crucial for management decisions in transplant-eligible patients...
  89. ncbi request reprint Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:623-30. 2006
    ..The current study describes the natural history of AMM in transplant-eligible patients and proposes a new prognostic scoring system that favorably compares with other established models...
  90. ncbi request reprint A critical review of anagrelide therapy in essential thrombocythemia and related disorders
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 46:641-50. 2005
    ..In the current review we provide basic drug information as well as a critical assessment of anagrelide treatment in ET and related disorders...
  91. ncbi request reprint Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia
    David Dingli
    Division of Hematology and Department of Internal Medicine, Mayo Clinic Rochester, MN, USA
    Br J Haematol 130:229-32. 2005
    ..In a preliminary fluorescence in situ hybridization study, the breakpoints on chromosome 6 in two additional cases were found to be telomeric to the gene for 51 kDa FK506-binding protein (FKBP51)...
  92. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  93. pmc Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
    Shirshendu Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 148:853-8. 2010
    ..Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome...
  94. pmc (A)symmetric stem cell replication and cancer
    David Dingli
    Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, United States of America
    PLoS Comput Biol 3:e53. 2007
    ..Mutations in several genes can lead to this process and may be at the root of the carcinogenic process...
  95. ncbi request reprint Multiple mutant clones in blood rarely coexist
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Phys Rev E Stat Nonlin Soft Matter Phys 77:021915. 2008
    ....
  96. pmc Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
    Tom Lenaerts
    MLG, Departement d informatique, Universite Libre de Bruxelles, Brussels, Belgium
    Haematologica 95:900-7. 2010
    ..However, the stochastic nature of hematopoiesis and recent clinical observations suggest that this view must be revisited...
  97. ncbi request reprint Acquired hematopoietic stem-cell disorders and mammalian size
    Joao V Lopes
    Centro de Física Teórica e Computacional and Departamento de Física da Faculdade de Ciências, Universidade Lisboa, Lisboa, Portugal
    Blood 110:4120-2. 2007
    ..Consequently, the smaller the active stem-cell pools, the better...
  98. ncbi request reprint A microenvironment based model of antimitotic therapy of Gompertzian tumor growth
    Frank Kozusko
    Department of Mathematics, Hampton University, Hampton, VA 23668, USA
    Bull Math Biol 69:1691-708. 2007
    ..Faster growing tumors respond better to dose density...
  99. pmc Cancer biology: infectious tumour cells
    David Dingli
    Nature 443:35-6. 2006
  100. pmc Immunoglobulin free light chains and solitary plasmacytoma of bone
    David Dingli
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 108:1979-83. 2006
    ..5 g/dL) or higher (high risk, n = 18). The corresponding progression rates at 5 years were significantly different in the low, intermediate, and high groups: 13%, 26%, and 62%, respectively (P < .001)...